Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) subsidiary Zhangyanming Tablet's clinical trial application has been approved.

Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., has recently received a "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration regarding the new functional indications of Zhangyanming Tablets. Zhangyanming Tablets have the effects of nourishing the liver and kidneys, alleviating eye cloudiness, and clearing the vision. They are used for symptoms caused by liver and kidney deficiency, such as dryness and discomfort in the eyes, monocular double vision, soreness and weakness of the lower back and knees, or mild vision decline; and for early to mid-stage age-related cataracts exhibiting the above symptoms. This drug is an already marketed traditional Chinese medicine compound formulation, and this application is for adding clinical trials for dry eye treatment.